Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The Progressive Corporation reported financial results for the month ended August 31, 2026, with net income of $951 million ($1.63 per share) on net premiums earned of $7.35 billion. The company's combined ratio for the month was 89.3, and total policies in force grew 7% year-over-year to 40.5 million.
BlossomHill Therapeutics reported financial results for the second quarter of 2026, highlighting the successful completion of its $168.3 million IPO in August. The company also noted clinical progress for BH-30643, which received FDA Fast Track designation for the treatment of advanced EGFR C797S-positive NSCLC.
Term
Q2 2026
“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter. In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels.”
Jean Cui, Ph.D., Founder, President and Chief Executive Officer
“With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”
Jean Cui, Ph.D., Founder, President and Chief Executive Officer
Upexi, Inc. reported financial results for the fiscal year ended June 30, 2026, with total revenue increasing to $25.0 million from $15.8 million in the prior year. The company reported a significant net loss of $246.1 million, primarily driven by $195.1 million in unrealized losses on its Solana (SOL) digital asset treasury. Despite the loss, the company fortified its balance sheet by retiring $19.5 million in convertible debt and increasing its cash position to $5.8 million.
Term
FY2026
“Fiscal 2026 marked the first full year of our Solana treasury strategy, and in a subdued market for digital assets we focused on what we could control. We fortified the balance sheet by retiring debt, increasing our cash position, and, subsequent to year-end, cutting the interest rate on our credit facility. We also completed our efficiency initiative, and expect staking revenue to exceed ongoing cash operating expenses beginning with the current quarter. The market will inevitably turn, and our improved balance sheet and expense base position us well.”